AT-Patch (ATP-C130/ATP-C70) vs Tempus ECG-Low EF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AT-Patch (ATP-C130/ATP-C70)
by ATsens Co.
VS
Tempus ECG-Low EF
by Tempus AI

AI Verdict

AT-Patch is an integrated wearable device and AI software solution focused on continuous, long-term ambulatory ECG monitoring for arrhythmia detection. In contrast, Tempus ECG-Low EF is an AI software designed to analyze existing 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction. While both utilize AI for cardiac ECG analysis, they address different diagnostic needs and employ distinct data acquisition methods.

Choose AT-Patch (ATP-C130/ATP-C70) if…

Choose AT-Patch if you require continuous, long-term cardiac monitoring for up to 14 days to detect intermittent arrhythmias and gather comprehensive ECG data in a patient's natural environment. This wearable device is ideal for patients needing a comfortable, shower-proof solution that minimizes disruption to daily activities while providing AI-powered analysis for enhanced arrhythmia detection.

View AT-Patch (ATP-C130/ATP-C70) →

Choose Tempus ECG-Low EF if…

Choose Tempus ECG-Low EF if you need an AI-powered software solution to quickly screen existing 12-lead ECG recordings for signs associated with low left ventricular ejection fraction (LVEF ≤40%) in patients 40 years or older. This tool is best suited for integration into clinical diagnostic workflows within healthcare facilities to aid clinicians in identifying patients at risk of heart failure for further evaluation.

View Tempus ECG-Low EF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature AT-Patch (ATP-C130/ATP-C70) Tempus ECG-Low EF
Pricing N/a Contact vendor
Deployment Wearable device for patients; analysis software deployed on-premise at medical institutions. Software, integrated into healthcare facility workflows
BAA Available Unknown Yes AI-estimated
FDA Status 1 AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AT-Patch (ATP-C130/ATP-C70)

AT-Patch prioritizes patient comfort and ease of use for extended, continuous monitoring with its compact, shower-proof wearable design and a smartphone app for live viewing and symptom recording. This offers a broader and more patient-centric definition of usability compared to a purely clinical software interface.

Clinical Value

Tie

Both tools offer significant, yet distinct, clinical value. AT-Patch provides long-term, continuous ECG monitoring for arrhythmia detection, while Tempus ECG-Low EF offers an AI-powered screening tool for heart failure risk from standard 12-lead ECGs. Their applications address different, but equally important, clinical needs in cardiac care.

Pricing & Value

Tie

Neither company provides public pricing information for their respective tools. Both state that pricing is available upon contacting the vendor, making a direct comparison of their pricing and perceived value impossible. Both likely operate on an enterprise sales model.

Enterprise Readiness

Tempus ECG-Low EF

Tempus ECG-Low EF explicitly confirms both HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for secure data handling and legal agreements in enterprise healthcare settings. AT-Patch's BAA status is not explicitly mentioned in the provided information.

Innovation

Tie

Both tools demonstrate significant innovation in different aspects of cardiology AI. AT-Patch innovates in its wearable technology for extended, patient-friendly monitoring, while Tempus ECG-Low EF innovates by extracting novel, predictive insights about heart failure risk from existing standard diagnostic tests using AI.

Support & Docs

Tempus ECG-Low EF

Tempus provides more detailed and transparent information regarding its multi-channel support options, including phone, email, and live chat, with specified business hours and response time targets for urgent and general inquiries. ATsens offers user manuals and a contact form but less explicit detail on support structure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature AT-Patch (ATP-C130/ATP-C70) Tempus ECG-Low EF
Tool Type/Primary Function Wearable ECG monitor for continuous cardiac monitoring. AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%).
Company ATsens Co. Tempus AI
Target Condition/Detection Focus Enhanced arrhythmia detection. Detects signs of low Left Ventricular Ejection Fraction (LVEF u226440%) in patients 40+ years at risk of heart failure.
ECG Type/Monitoring Duration Up to 14 days of continuous ECG monitoring (ATP-C130). Analyzes resting, non-ambulatory 12-lead ECG recordings.
Key AI Functionality AI/machine learning algorithms for ECG analysis (AT-Report software). AI-powered algorithm for ECG analysis, specifically detecting signs of low LVEF.
Categories Cardiology AI, Wearables & Remote Monitoring (RPM) Cardiology AI

Videos

Demos, reviews, and walkthroughs featuring AT-Patch (ATP-C130/ATP-C70) and Tempus ECG-Low EF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

AT-Patch is an ambulatory ECG monitor designed for continuous cardiac monitoring, primarily for arrhythmia detection over an extended period, up to 14 days. Tempus ECG-Low EF is an AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%), aiding in identifying patients 40 years or older at risk of heart failure.
AT-Patch analyzes continuous ECG data collected directly from its wearable device, which is worn by the patient. In contrast, Tempus ECG-Low EF analyzes resting, non-ambulatory 12-lead ECG recordings, typically collected at a healthcare facility.
AT-Patch provides AI/machine learning-powered analysis for enhanced arrhythmia detection, classifying ECG patterns and providing data analysis for various arrhythmia types. Tempus ECG-Low EF delivers a binary output (Low LVEF Detected / Not Detected) to help clinicians identify patients who may require further evaluation for low LVEF.
AT-Patch is intended for patients 18 years or older who may be asymptomatic or have transient symptoms such as palpitations, shortness of breath, or dizziness, requiring long-term continuous cardiac monitoring. Tempus ECG-Low EF is specifically for patients 40 years or older at risk of heart failure, including those with conditions like atrial fibrillation, diabetes, or hypertension, to detect signs of low LVEF.
AT-Patch requires patients to wear the device, with its analysis software (AT-Report) deployed on-premise at medical institutions for review. Tempus ECG-Low EF is designed to integrate directly into existing healthcare facility workflows to analyze standard 12-lead ECG recordings, providing its output within that established system.
AT-Patch utilizes AI/machine learning algorithms for comprehensive ECG analysis to enhance the detection and classification of various arrhythmias. Tempus ECG-Low EF employs an AI-powered algorithm specifically trained on a large dataset to detect signs associated with low LVEF (u226440%) from 12-lead ECGs.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring AT-Patch (ATP-C130/ATP-C70) or Tempus ECG-Low EF

Backers

Who funded each tool's parent company.

Tempus ECG-Low EF

AI Tool Finder
AI-powered search. Results may not be comprehensive.